Insight Molecular Diagnostics Inc. (IMDX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$135.15M

MomentumView details →

1D Return

+0.24%

YTD Return

−45.67%

RSI (14)

42.4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−2.6x

Market Cap

$135.15M

RSI (14)

42.4

MomentumView details →

1D Return

+0.24%

YTD Return

−45.67%

ProfitabilityView details →

Gross Margin

11.17%

Net Margin

−2955.63%

EBITDA Margin

−2803.47%

ROE (TTM)

231.74%

ROA (TTM)

−167.64%

Asset Turnover

0.05x

GrowthView details →

Revenue YoY

−60.77%

EPS YoY

+56.27%

FCF YoY

−30.29%

Revenue CAGR 3Y

+61.76%

EPS CAGR 3Y

+64.60%

EBITDA YoY

+23.69%

EarningsView details →

EPS (Actual)

−$0.31

EPS Surprise

−22.07%

Beats (12Q)

7/12

Next Q EPS Est

−$0.23

Avg Surprise (4Q)

42.20%

Rev Surprise

−45.37%

Capital & dividendView details →

Debt/Equity

−0.12x

Current Ratio

2.00x

Quick Ratio

1.98x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

1.67M

Net Income (TTM)

−49.36M

Op. CF (TTM)

−26.95M

Next earningsNov 9, 2026 →

Latest newsMore news →

Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy that expands coverage for donor-derived cell-free DNA testing in transplant care.50d ago

Similar companies

TuHURA Biosciences, Inc.HURA Conexeu Sciences Inc.CNXU vTv Therapeutics Inc.VTVT Neonc Technologies Holdings, Inc.NTHI Equillium, Inc.EQ Tiziana Life Sciences LtdTLSA Find similar companies →

Latest newsMore news →

Insight Molecular Diagnostics Inc. highlighted a favorable new Medicare policy that expands coverage for donor-derived cell-free DNA testing in transplant care.50d ago